Requiring an Amyloid-Β1-42 Biomarker for Prodromal Alzheimer's Disease or Mild Cognitive Impairment Does Not Lead to More Efficient Clinical Trials
Alzheimer's and Dementia - United States
doi 10.1016/j.jalz.2010.07.004
Full Text
Open PDFAbstract
Available in full text
Categories
Date
September 1, 2010
Authors
Publisher
Wiley